Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
60%
Ph phase_1
1
20%
Ph phase_2
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)

Trials by Status

withdrawn120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00004202
completedphase_3

Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

NCT00005887
completedphase_1

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT00005855
withdrawnphase_3

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00055887
completedphase_3

Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer

NCT00083304

Clinical Trials (5)

Showing 5 of 5 trials
NCT00004202Phase 2

Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer

Completed
NCT00005887Phase 3

Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

Completed
NCT00005855Phase 1

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

Completed
NCT00055887Phase 3

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn
NCT00083304Phase 3

Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5